此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HMPL-760 脉冲 R-GemOx 与安慰剂加 R-GemOx 在复发/难治性 DLBCL 中的研究

2026年9月23日 更新者:Hutchmed

一项 II 期随机对照研究,旨在评估 HMPL-760 加 R-GemOx 与安慰剂加 R-GemOx 在复发/难治性弥漫性大 B 细胞淋巴瘤 (R/R DLBCL) 患者中的疗效、安全性和药代动力学

The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

研究概览

详细说明

A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination with R-GemOx versus Placebo in Combination with R-GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL). The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

研究类型

介入性

注册 (实际的)

61

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Fujian
      • Fuzhou、Fujian、中国
        • Fujian Medical University Union Hospital
    • Guangdong
      • Guangzhou、Guangdong、中国
        • Sun Yat-sen University Cancer Center
    • Guangxi
      • Nanning、Guangxi、中国
        • Guangxi Medical University Cancer Hospital
    • Hebei
      • Wuhan、Hebei、中国
        • Wuhan Union Hospital of China
    • Heilongjiang
      • Harbin、Heilongjiang、中国
        • Harbin Medical University Cancer Hospital
      • Harbin、Heilongjiang、中国
        • Harbin First Hospital
    • Henan
      • Zhengzhou、Henan、中国
        • Henan Cancer Hospital
      • Zhengzhou、Henan、中国
        • The First Affiliated Hospital of Zhengzhou University
    • Hunan
      • Changsha、Hunan、中国
        • Hunan Cancer Hospital
    • Jiangxi
      • Nanchang、Jiangxi、中国
        • Jiangxi Cancer Hospital
      • Nanchang、Jiangxi、中国
        • The First Affiliated Hospital of Nanchang University
    • Liaoning
      • Shenyang、Liaoning、中国
        • Shengjing Hospital of China Medical University
    • Shandong
      • Jinan、Shandong、中国
        • Shandong Cancer Hospital & Institute
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    • Sichuan
      • Chengdu、Sichuan、中国
        • West China Hospital of Sichuan University
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Sign the Informed consent form(ICF) and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV):
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. Toxicities from prior anticancer therapy not resolved to Grade ≤ 1 (except for alopecia and decreased appetite);
  8. Clinically significant active infection;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Group A: HMPL-760 planned dose 1 once daily (QD) in combination with R-GemOx regimen

Group A: Patients will receive HMPL-760 planned dose 1 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

HMPL-760 planned dose 1 daily (QD) orally

R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

其他名称:
  • 利妥昔单抗注射液, 注射用盐酸吉西他滨, 注射用盐酸吉西他滨
安慰剂比较:Group B: HMPL-760 placebo planned dose 1 once daily (QD) in combination with R-GemOx regimen

Patients will receive HMPL-760 placebo planned dose 1 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

其他名称:
  • 利妥昔单抗注射液, 注射用盐酸吉西他滨, 注射用盐酸吉西他滨

HMPL-760 placebo planned dose 1 daily (QD) orally

实验性的:Group C: HMPL-760 planned dose 2 once daily (QD) in combination with R-GemOx regimen

Patients will receive HMPL-760 planned dose 2 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

其他名称:
  • 利妥昔单抗注射液, 注射用盐酸吉西他滨, 注射用盐酸吉西他滨

HMPL-760 planned dose 2 daily (QD) orally

安慰剂比较:Group D: HMPL-760 placebo planned dose 2 once daily (QD) in combination with R-GemOx regimen

Patients will receive HMPL-760 placebo planned dose 2 once daily (QD) orally from Cycle 1 Day 1 until disease progression(PD), patient death, intolerable toxicity, etc., in combination with R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m^2 ivgtt is given, followed by oxaliplatin 100 mg/m^2 ivgtt on day 2 of each cycle.

其他名称:
  • 利妥昔单抗注射液, 注射用盐酸吉西他滨, 注射用盐酸吉西他滨

HMPL-760 placebo planned dose 2 daily (QD) orally

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS)
大体时间:Up to approximately 2 years

Progression-free survival (PFS): Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately 2 years

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:Up to approximately 2 years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR), as assessed by investigator.

Up to approximately 2 years
Complete response (CR) rate
大体时间:Up to approximately 2 years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR), as assessed by investigator.

Up to approximately 2 years
Duration of response (DoR)
大体时间:Up to approximately 2 years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first, as assessed by investigator.

Up to approximately 2 years
Clinical benefit rate (CBR)
大体时间:Up to approximately 2 years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD).

Up to approximately 2 years
Time to response (TTR)
大体时间:Up to approximately 2 years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR), as assessed by investigator.

Up to approximately 2 years
Overall survival (OS)
大体时间:Up to approximately 2 years

Overall Survival (OS) is defined as the time from randomization to death due to any cause.

Up to approximately 2 years
Safety Endpoints of adverse events
大体时间:Up to approximately 2 years

Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of serious adverse events (SAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).

Up to approximately 2 years
Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx
大体时间:At the end of Cycle 7 (each cycle is 21 days)

Trough plasma concentration (Ctrough) of drug

At the end of Cycle 7 (each cycle is 21 days)
Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx
大体时间:At the end of Cycle 7 (each cycle is 21 days)

Maximum observed concentration, occurring at time Tmax at steady-state (Cmax,ss) of drug

At the end of Cycle 7 (each cycle is 21 days)
Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx
大体时间:At the end of Cycle 7 (each cycle is 21 days)

Time of maximum observed concentration at steady-state(Tmax,ss) of drug

At the end of Cycle 7 (each cycle is 21 days)
Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx
大体时间:At the end of Cycle 7 (each cycle is 21 days)

The partial area from dosing time to dosing time plus Tau at steady-state (AUCss) of drug

At the end of Cycle 7 (each cycle is 21 days)
Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx
大体时间:At the end of Cycle 7 (each cycle is 21 days)

Apparent clearance at steady-state (CLss/F) of drug (if applicable)

At the end of Cycle 7 (each cycle is 21 days)
Pharmacokinetic(PK) profile of HMPL-760 in combination with R-GemOx
大体时间:At the end of Cycle 7 (each cycle is 21 days)

Apparent volume of distribution at steady-state (Vz,ss/F) of drug (if applicable)

At the end of Cycle 7 (each cycle is 21 days)

其他结果措施

结果测量
措施说明
大体时间
Biomarker assessment
大体时间:Up to approximately 2 years

To evaluate the correlation between potential biomarkers and the prognosis of patients treated with this regimen. Tumor tissue or blood samples will be examined to detect the gene expression of MYD88.

Up to approximately 2 years
Metabolite analysis of HMPL-760 in combination with R-GemOx
大体时间:At the end of Cycle 7 (each cycle is 21 days)

Analysis metabolite of HMPL-760 in combination with R-GemOx

At the end of Cycle 7 (each cycle is 21 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Weili Zhao、Ruijin Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年11月5日

初级完成 (实际的)

2026年5月23日

研究完成 (实际的)

2026年5月23日

研究注册日期

首次提交

2024年9月8日

首先提交符合 QC 标准的

2024年9月14日

首次发布 (实际的)

2024年9月19日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅